Related Experiment Video
Updated: Aug 17, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
[Mild cognitive impairment: A review of the literature]
A K Hödl1, R M Bonelli, H P Kapfhammer
1Universitätsklinik für Psychiatrie, Medizinische Universität Graz.
Abstract:
People with MCI suffer from a moderate memory impairment, from deficits in attention and cognitive flexibility but do not fulfil the diagnostic criteria of dementia. These patients feel forgetful, and sometimes may have problems with their jobs and families because of their forgetfulness. In many cases (10-15% per year), MCI is leading to Alzheimer's disease. The sooner MCI is diagnosed and treated, the better the transition into Alzheimer's disease may perhaps be delayed. The diagnostic instruments are the same as for the diagnosis of Alzheimer's disease: biomarkers of the cerebrospinal fluid, neuroimaging and neuropsychological testing. Neuropsychological testing already shows deficits, even when neuroimaging findings still seem to be normal. Therapy of MCI is basically like the treatment of Alzheimer's disease: symptomatic treatment with cholinesterase-inhibitors or antioxidants, and compensatory psychological approaches.
Insights
Mild cognitive impairment (MCI) involves memory and attention deficits but isn't dementia. Early diagnosis and treatment of MCI can help delay the progression to Alzheimer's disease.
Area of Science:
- Neurology
- Neuroscience
- Geriatrics
Context:
- Mild cognitive impairment (MCI) is characterized by moderate memory loss and cognitive deficits, distinct from dementia.
- Individuals with MCI experience forgetfulness impacting daily life, work, and family relationships.
- A significant percentage of MCI cases (10-15% annually) progress to Alzheimer's disease.
Purpose:
- To highlight the importance of early diagnosis and treatment for mild cognitive impairment (MCI).
- To discuss diagnostic methods and therapeutic strategies for MCI.
- To emphasize the potential to delay Alzheimer's disease progression through timely intervention.
Summary:
- MCI presents with memory impairment and cognitive flexibility deficits, not meeting dementia criteria.
- Diagnostic tools for MCI include cerebrospinal fluid biomarkers, neuroimaging, and neuropsychological testing.
- Neuropsychological testing can detect deficits even before neuroimaging abnormalities appear.
- Therapies for MCI mirror Alzheimer's disease treatments, including cholinesterase-inhibitors, antioxidants, and psychological support.
Impact:
- Early detection and intervention in MCI can potentially slow the transition to Alzheimer's disease.
- Understanding MCI's progression is crucial for developing effective management strategies.
- Timely treatment may improve quality of life for individuals with MCI and their families.
Related Concept Videos
Cognitive Development During Adulthood
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction
Dementia
The progression of dementia is generally gradual.
Intellectual Disability

